Creo Medical Group (FRA:1RC) FFO


FRA:1RC Creo Medical Group PLC FRA:1RC
53 GF Score
Price €0.15
GF Value €0.18
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group FFO?

FFO (Funds from operations) only applies to REITs.

FRA:1RC
53GF Score
Creo Medical Group PLC FRA:1RC
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Creo Medical Group (FRA:1RC) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of €0.15 is trading 19.4% below its estimated GF Value™ of €0.18.

Key valuation signals for FRA:1RC:

  • FFO:
  • GF Value™: €0.18 vs. price of €0.15 (19.4% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the FRA:1RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score

Get the complete analysis for FRA:1RC

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.18
GF Value